Cellomatics Founder & CEO Dr Shailendra Singh provides his expert opinion on the evolution of assays for immuno-oncology research in an article featured in the Winter 2022/23 publication of Drug Discovery World – a multi-platform global voice for the drug discovery community.
The article, titled ‘The evolution of assays for immuno-oncology research’ looks at the history of immuno-oncology, the rising demand in the assay market, and how the bespoke and customised approach can be used to further drug development.
View the Drug Discovery World article here.
Cellomatics is a preclinical immuno-oncology CRO offering expertise in robust and reproducible immuno-oncology related assays.
Find out more about our service offering here.